Biomarker Discovery and Validation: Statistical Considerations

被引:81
|
作者
Ou, Fang-Shu [1 ]
Michiels, Stefan [2 ]
Shyr, Yu [3 ]
Adjei, Alex A. [4 ]
Oberg, Ann L. [1 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA
[2] Univ Paris Saclay, Dept Biostat & Epidemiol, Labelel Ligue Canc, INSERM,Gustave Roussy,Oncostat U1018,CESP, Villejuif, France
[3] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA
[4] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Biomarker; Exploratory analysis; Confirmation analysis; Clinical trial; CANCER; SPECIMENS; IMPACT; BIAS;
D O I
10.1016/j.jtho.2021.01.1616
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes. Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes. ? 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:537 / 545
页数:9
相关论文
共 50 条
  • [1] Biomarker discovery and validation
    Rifai, Nader
    Gerszten, Robert E.
    CLINICAL CHEMISTRY, 2006, 52 (09) : 1635 - 1637
  • [2] Statistical Considerations of Optimal Study Design for Human Plasma Proteomics and Biomarker Discovery
    Zhou, Cong
    Simpson, Kathryn L.
    Lancashire, Lee J.
    Walker, Michael J.
    Dawson, Martin J.
    Unwin, Richard D.
    Rembielak, Agata
    Price, Patricia
    West, Catharine
    Dive, Caroline
    Whetton, Anthony D.
    JOURNAL OF PROTEOME RESEARCH, 2012, 11 (04) : 2103 - 2113
  • [3] Cancer biomarker discovery and validation
    Goossens, Nicolas
    Nakagawa, Shigeki
    Sun, Xiaochen
    Hoshida, Yujin
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (03) : 256 - 269
  • [4] Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation
    Nakayasu, Ernesto S.
    Gritsenko, Marina
    Piehowski, Paul D.
    Gao, Yuqian
    Orton, Daniel J.
    Schepmoes, Athena A.
    Fillmore, Thomas L.
    Frohnert, Brigitte I.
    Rewers, Marian
    Krischer, Jeffrey P.
    Ansong, Charles
    Suchy-Dicey, Astrid M.
    Evans-Molina, Carmella
    Qian, Wei-Jun
    Webb-Robertson, Bobbie-Jo M.
    Metz, Thomas O.
    NATURE PROTOCOLS, 2021, 16 (08) : 3737 - 3760
  • [5] Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation
    Ernesto S. Nakayasu
    Marina Gritsenko
    Paul D. Piehowski
    Yuqian Gao
    Daniel J. Orton
    Athena A. Schepmoes
    Thomas L. Fillmore
    Brigitte I. Frohnert
    Marian Rewers
    Jeffrey P. Krischer
    Charles Ansong
    Astrid M. Suchy-Dicey
    Carmella Evans-Molina
    Wei-Jun Qian
    Bobbie-Jo M. Webb-Robertson
    Thomas O. Metz
    Nature Protocols, 2021, 16 : 3737 - 3760
  • [6] Biomarker discovery and validation: the tide is turning
    Nice, Edouard
    EXPERT REVIEW OF PROTEOMICS, 2013, 10 (06) : 505 - 507
  • [7] Current challenges in biomarker discovery and validation
    Ransohoff, David F.
    CANCER BIOMARKERS, 2008, 4 (03) : 126 - 127
  • [8] Proteomic Workflows for Biomarker Identification Using Mass Spectrometry - Technical and Statistical Considerations during Initial Discovery
    Orton, Dennis J.
    Doucette, Alan A.
    PROTEOMES, 2013, 1 (02): : 109 - 127
  • [9] Statistical considerations when analyzing biomarker data
    Beam, Craig A.
    CLINICAL IMMUNOLOGY, 2015, 161 (01) : 31 - 36
  • [10] Neuroimaging-based biomarker discovery and validation
    Woo, Choong-Wan
    Wager, Tor D.
    PAIN, 2015, 156 (08) : 1379 - 1381